<DOC>
	<DOCNO>NCT00361413</DOCNO>
	<brief_summary>Alefacept ( AMEVIVE® ) immunosuppressive dimeric fusion protein . It show interfere lymphocyte activation specifically bind lymphocyte antigen , CD2 , inhibit LFA-3/CD2 interaction . Alefacept evaluate two randomize , double-blind , placebo-controlled study adult chronic ( &gt; 1 year ) plaque psoriasis minimum body surface area involvement 10 % candidate previously receive systemic therapy phototherapy . The response alefacept significantly good study . In study , onset response alefacept treatment ( define least 50 % reduction baseline Psoriasis Area Severity Index ( PASI ) ) begin 60 day start therapy . Graft versus host disease ( GVHD ) ominous side effect allogeneic stem cell transplantation ( SCT ) . It cause severe inflammatory process , usually locate skin , gut liver . Treatment GVHD consist various immuno-suppressive immuno-modulating drug , include steroid , cyclosporine , tacrolimus , methotrexate etc . These drug unfortunately also cause severe immunologic failure make patient prone infection malignancy , medication-specific side effect . In spite effect immune system , patient achieve control GVHD , usually rapidly lead death . Despite use innovative immunosuppressive modality , prognosis steroid resistant GVHD usually poor . It show CD2 depletion allograft could prevent GVHD . Alefacept never systemically tried GVHD A phase II study BTI-322 , rat monoclonal IgG2b direct CD2 antigen steroid-refractory acute GVHD show total response rate 55 % . We show alefacept might beneficial effect control steroid resistant aGVHD chronic GVHD . It also show dramatically change nature transfusion associate GVHD .</brief_summary>
	<brief_title>Alefacept Prevention Graft Versus Host Disease ( GVHD )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>1 . Patient age 1475 year old disease necessitate allogeneic SCT . 2 . In order increase security , full match donor allow must willing capable donate peripheral blood stem cell preferably , bone marrow progenitor cell use conventional technique , lymphocyte indicate . 3 . Patients must sign write informed consent . 4 . Patients must ECOG PS ≤ 2 ; creatinine &lt; 2.0 mg/dl ; ejection fraction &gt; 40 % ; DLCO &gt; 50 % predict ; serum bilirubin &lt; 3 gm/dl ; elevate GPT GOT &gt; 3 x normal value . 1 . Not fulfil inclusion criterion . 2 . Active lifethreatening infection . 3 . Overt untreated infection . 4 . Hypersensitivity alefacept . 5 . HIV seropositivity , Hepatitis B C antigen positivity active hepatitis . 6 . Pregnant lactating woman . 7 . Donor contraindication ( HIV seropositive confirm western blot ) . 8 . Hepatitis B antigenemia . 9 . Evidence bone marrow disease . 10 . Unable donate bone marrow peripheral blood due concurrent medical condition . 11 . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Stem cell transplantation</keyword>
	<keyword>GVHD</keyword>
	<keyword>Graft Versus Host Disease</keyword>
</DOC>